ICU Management of Manganese Toxicity (Welder's Encephalopathy): A Comprehensive Review for Critical Care Practitioners

Dr Neeraj Manikath, claude.ai

Abstract

Manganese toxicity, particularly in occupational settings such as welding, presents unique challenges in critical care management. This review synthesizes current evidence on the pathophysiology, diagnostic approaches, and therapeutic interventions for acute manganese encephalopathy. We emphasize the critical diagnostic role of T1-weighted MRI hyperintensity patterns, evaluate chelation strategies comparing EDTA and DMSA, and discuss the emerging role of high-dose levodopa as bridge therapy. Early recognition and aggressive management can significantly impact neurological outcomes in this potentially devastating condition.

Keywords: Manganese toxicity, welder's encephalopathy, chelation therapy, levodopa, critical care

Introduction

Manganese (Mn) toxicity represents a complex neurometabolic emergency that demands sophisticated critical care management. While chronic occupational exposure typically leads to gradual onset manganism, acute high-dose exposures can precipitate fulminant encephalopathy requiring immediate intensive care intervention. The condition disproportionately affects welders, miners, and steel workers exposed to manganese-containing fumes and particles.

The pathophysiology involves selective accumulation of manganese in the basal ganglia, particularly the globus pallidus and substantia nigra, leading to dopaminergic dysfunction and characteristic movement disorders resembling Parkinson's disease. Unlike idiopathic Parkinson's disease, manganese-induced parkinsonism typically shows poor response to standard dopaminergic therapy and may be irreversible without prompt intervention.

Pathophysiology and Neurochemical Basis

Manganese crosses the blood-brain barrier via the divalent metal transporter (DMT1) and accumulates preferentially in astrocytes and neurons of the basal ganglia. The metal disrupts mitochondrial function, generates reactive oxygen species, and interferes with dopamine synthesis and metabolism. This leads to a cascade of neuroinflammation, oxidative stress, and eventual neuronal death.

Pearl 1: The selectivity for basal ganglia accumulation explains why movement disorders dominate the clinical picture, but cognitive and psychiatric symptoms often precede motor manifestations by weeks to months.

Unlike other heavy metal toxicities, manganese primarily affects the globus pallidus rather than the caudate nucleus, distinguishing it from Wilson's disease or carbon monoxide poisoning on neuroimaging.

Clinical Presentation and Recognition

Acute Phase

Altered mental status ranging from confusion to coma
Psychiatric symptoms: irritability, aggression, psychosis
Early motor signs: bradykinesia, rigidity, postural instability
Dystonic movements, particularly involving facial muscles
Respiratory depression in severe cases

Subacute Progression

Development of characteristic "cock-walk" gait
Masklike facies and monotonous speech
Progressive bradykinesia and muscle rigidity
Cognitive impairment and executive dysfunction

Oyster 1: Beware of the "manganese madness" - acute psychiatric presentations may be mistaken for primary psychiatric disorders, delaying appropriate treatment. Always inquire about occupational exposure in patients presenting with acute behavioral changes.

Diagnostic Imaging: The T1-MRI Gold Standard

The pathognomonic finding in manganese toxicity is bilateral T1-weighted hyperintensity in the globus pallidus, with additional involvement of the substantia nigra, subthalamic nucleus, and dentate nucleus in severe cases. This finding is virtually diagnostic when combined with appropriate exposure history.

Hack 1: T1 hyperintensity on MRI with normal EEG findings is the key diagnostic clue that differentiates manganese toxicity from other encephalopathies. The EEG typically remains normal even in severe cases, unlike hepatic or uremic encephalopathy.

MRI Grading System

Grade I: Isolated globus pallidus involvement
Grade II: Extension to substantia nigra
Grade III: Additional dentate nucleus involvement
Grade IV: Widespread basal ganglia and brainstem involvement

Higher grades correlate with severity of clinical symptoms and predict poorer therapeutic response.

Laboratory Assessment

Essential Investigations

Serum manganese levels: Normal range 0.4-0.85 μg/L; levels >2.0 μg/L suggest toxicity
Whole blood manganese: More reliable than serum in chronic exposure
24-hour urine manganese: Elevated in acute exposure (normal <8 μg/24h)
Complete metabolic panel: Assess hepatic and renal function
Arterial blood gas: Monitor for respiratory depression

Pearl 2: Serum manganese levels may normalize rapidly after exposure cessation, making them unreliable in delayed presentations. MRI findings persist long after normalization of biomarkers.

Additional Studies

Cerebrospinal fluid analysis (usually normal)
Thyroid function tests (manganese can affect thyroid metabolism)
Copper and ceruloplasmin levels (exclude Wilson's disease)

The Chelation Dilemma: EDTA vs. DMSA

The choice of chelating agent remains one of the most contentious aspects of manganese toxicity management. Both calcium disodium EDTA and dimercaptosuccinic acid (DMSA) have theoretical benefits and practical limitations.

Calcium Disodium EDTA (CaNa2EDTA)

Advantages:

Established efficacy in heavy metal poisoning
Rapid onset of action
Well-studied pharmacokinetics
Available in IV formulation for critically ill patients

Protocol:

Loading dose: 1000-1500 mg/m² IV over 1-2 hours
Maintenance: 1000 mg/m²/day divided into 2-3 doses
Duration: 3-5 days, repeated after 48-72 hour intervals
Maximum: 3 courses

Limitations:

Nephrotoxicity risk
Requires adequate hydration and monitoring
May redistribute manganese to brain in some cases

DMSA (Dimercaptosuccinic Acid)

Advantages:

Oral administration possible
Better blood-brain barrier penetration
Lower nephrotoxicity profile
More selective for heavy metals

Protocol:

Initial dose: 10 mg/kg orally every 8 hours for 5 days
Maintenance: 10 mg/kg every 12 hours for 14 days
Can be given via nasogastric tube in unconscious patients

Limitations:

Limited availability
Slower onset of action
Less extensive clinical experience
May not be suitable for severe acute presentations

Hack 2: In acute neurologic deterioration with altered consciousness, start with IV CaNa2EDTA for rapid mobilization, then transition to oral DMSA for maintenance therapy once the patient stabilizes. This combination approach maximizes both immediate efficacy and long-term safety.

Novel Chelation Approaches

Emerging evidence suggests that combination therapy with multiple chelating agents may be superior to monotherapy. Some centers are exploring:

N-acetylcysteine as adjunctive therapy
Para-aminosalicylic acid (PAS) for its iron-chelating properties
Deferoxamine in cases with concurrent iron overload

Bridge Therapy: High-Dose Levodopa Strategy

Unlike idiopathic Parkinson's disease, manganese-induced parkinsonism typically shows poor response to standard levodopa doses. However, high-dose levodopa therapy has emerged as a crucial bridge intervention while chelation takes effect.

Levodopa Protocol for Manganese Toxicity

Initial Dosing:

Start with levodopa/carbidopa 25/100 mg three times daily
Escalate rapidly to 50/200 mg four times daily
Target dose: 1000-1500 mg levodopa daily (higher than standard PD treatment)

Monitoring Parameters:

Blood pressure (risk of hypotension)
Cardiac rhythm (risk of arrhythmias)
Mental status (risk of hallucinations)
Dyskinesia development

Pearl 3: The response to levodopa in manganese toxicity is often delayed compared to idiopathic Parkinson's disease. Allow 7-10 days at therapeutic doses before declaring treatment failure.

Adjunctive Dopaminergic Therapy

Pramipexole: 0.125 mg TID, titrated to 1.5 mg TID
Ropinirole: 0.25 mg TID, titrated to 8 mg TID
Amantadine: 100 mg BID for dyskinesia prevention

Hack 3: Combine high-dose levodopa with a dopamine agonist for synergistic effect. This dual approach often produces better motor improvement than either agent alone.

Critical Care Management Pearls

Respiratory Management

Manganese toxicity can cause respiratory depression through brainstem involvement. Monitor closely for:

Decreased respiratory drive
Aspiration risk from dysphagia
Sleep-disordered breathing

Management:

Serial arterial blood gases
Consider elective intubation for GCS <8
Non-invasive ventilation for mild respiratory insufficiency

Nutritional Considerations

Oyster 2: Iron deficiency paradoxically increases manganese absorption via DMT1 upregulation. Ensure adequate iron stores but avoid excess iron supplementation which can worsen oxidative stress.

Nutritional interventions:

Iron optimization (ferritin 50-150 ng/mL)
Zinc supplementation (competes with manganese for absorption)
Antioxidant therapy: Vitamin E, selenium, CoQ10

Seizure Management

Although uncommon, seizures may occur in severe cases:

Standard anticonvulsants are effective
Avoid phenytoin (may worsen movement disorders)
Levetiracetam is preferred first-line agent

Monitoring and Follow-up

ICU Monitoring Parameters

Neurological assessments every 2-4 hours
Unified Parkinson's Disease Rating Scale (UPDRS) daily
Renal function during chelation therapy
Serum manganese levels every 48-72 hours
MRI repeat at 1 week to assess response

Long-term Outcomes

Recovery patterns vary significantly:

Motor symptoms may improve over months to years
Cognitive function often shows better recovery than motor function
Early intervention (within 1-2 months of exposure) predicts better outcomes
Some patients require long-term dopaminergic therapy

Pearl 4: Document baseline UPDRS scores and cognitive assessment for medicolegal purposes, as occupational manganese exposure often results in workers' compensation claims.

Special Populations

Pediatric Considerations

Children may be more susceptible to manganese toxicity:

Lower chelation doses: CaNa2EDTA 25-35 mg/kg/day
DMSA: 10 mg/kg every 8 hours
More frequent neurological monitoring
Consider developmental assessment

Pregnancy

Limited data on treatment during pregnancy:

DMSA appears safer than EDTA
Levodopa is pregnancy category C
Multidisciplinary approach with obstetrics

Future Directions and Research

Emerging Therapies

Neuroprotective agents: Minocycline, riluzole
Anti-inflammatory approaches: Curcumin, resveratrol
Stem cell therapy: Experimental in animal models
Deep brain stimulation: For refractory cases

Biomarker Development

Research focuses on:

Earlier detection markers
Predictors of therapeutic response
Imaging biomarkers for prognosis

Clinical Decision Algorithm

Suspected Mn Toxicity
        ↓
T1-MRI + Exposure History
        ↓
Confirmed Diagnosis
        ↓
Severity Assessment
   ↓         ↓
Mild-Mod    Severe
   ↓         ↓
DMSA      CaNa2EDTA
Oral      IV + ICU
   ↓         ↓
  Add High-Dose
  Levodopa
        ↓
Monitor Response
   ↓         ↓
Improving   No Response
   ↓         ↓
Continue   Consider
Therapy    Alternative
          Chelation

Key Clinical Pearls Summary

T1 MRI hyperintensity with normal EEG is pathognomonic
Serum manganese levels normalize rapidly - don't rely on delayed measurements
High-dose levodopa (up to 1500mg daily) is often required for motor response
Iron deficiency increases manganese absorption - optimize but don't oversupplement
Early intervention (within 2 months) predicts better outcomes
Combination chelation therapy may be superior to monotherapy
Response to levodopa is delayed compared to idiopathic Parkinson's disease

Conclusion

Manganese toxicity represents a complex neurometabolic emergency requiring sophisticated critical care management. The combination of early recognition through characteristic MRI findings, aggressive chelation therapy, and high-dose dopaminergic support offers the best chance for neurological recovery. As our understanding of the pathophysiology advances, novel therapeutic approaches continue to emerge, offering hope for improved outcomes in this challenging condition.

The key to successful management lies in maintaining high clinical suspicion, rapid diagnosis, and immediate initiation of appropriate therapy. Critical care physicians must be prepared to manage not only the acute neurological manifestations but also the complex decisions surrounding chelation choice and timing.

References

Aschner M, Erikson KM. Manganese neurotoxicity and oxidative damage. Adv Exp Med Biol. 2001;500:435-451.
Bowler RM, Gysens S, Diamond E, et al. Neuropsychological sequelae of exposure to welding fumes in a group of occupationally exposed men. Int J Hyg Environ Health. 2003;206(6):517-529.
Crossgrove J, Zheng W. Manganese toxicity upon overexposure. NMR Biomed. 2004;17(8):544-553.
Discalzi G, Pira E, Herrero Hernandez E, et al. Occupational Mn parkinsonism: magnetic resonance imaging and clinical patterns following CaNa2-EDTA chelation. Neurotoxicology. 2000;21(5):863-866.
Guilarte TR. Manganese and Parkinson's disease: a critical review and new findings. Environ Health Perspect. 2010;118(8):1071-1080.
Hernández EH, Discalzi G, Valentini C, et al. Follow-up of patients affected by manganese-induced Parkinsonism after treatment with CaNa2EDTA. Neurotoxicology. 2006;27(3):333-339.
Jankovic J. Searching for a relationship between manganese and welding and Parkinson's disease. Neurology. 2005;64(12):2021-2028.
Klaassen CD, Liu J, Choudhuri S. Metallothionein: an intracellular protein to protect against cadmium toxicity. Annu Rev Pharmacol Toxicol. 1999;39:267-294.
Lucchini RG, Martin CJ, Doney BC. From manganism to manganese-induced parkinsonism: a conceptual model based on the evolution of exposure. Neuromolecular Med. 2009;11(4):311-321.
Milatović D, Zaja-Milatović S, Gupta RC, et al. Oxidative damage and neurodegeneration in manganese-induced neurotoxicity. Toxicol Appl Pharmacol. 2009;240(2):219-225.
Pal PK, Samii A, Calne DB. Manganese neurotoxicity: a review of clinical features, imaging and pathology. Neurotoxicology. 1999;20(2-3):227-238.
Perl DP, Olanow CW. The neuropathology of manganese-induced Parkinsonism. J Neuropathol Exp Neurol. 2007;66(8):675-682.
Rodier J. Manganese poisoning in Moroccan miners. Br J Ind Med. 1955;12(1):21-35.
Wasserman GA, Liu X, Parvez F, et al. Water manganese exposure and children's intellectual function in Araihazar, Bangladesh. Environ Health Perspect. 2006;114(1):124-129.
Zheng W, Fu SX, Dydak U, Cowan DM. Biomarkers of manganese intoxication. Neurotoxicology. 2011;32(1):1-8.

Wednesday, July 23, 2025

ICU Management of Welder's Encephalopathy